Hologic (HOLX), a leading player in meeting the healthcare needs of women, has taken a step forward for promoting several new and innovative breast health and medical imaging products. It is participating in the 21st Annual National Interdisciplinary Breast Center Conference (NCBC), Las Vegas, during 12th to 16th March 2011 with its Selenia Dimension’s next-generation 3D digital mammography system which has received approval from the US Food and Drug Administration (FDA) in February 2011.

Also the company will exhibit some new and improved technologies in imaging like Affirm upright breast biopsy guidance system, ImageChecker 3D Calc computer-aided detection and MultiCare Platinum breast biopsy table. Moreover, with Hologic’s acquisition of Canada-based Sentinelle Medical in August 2010, a leading provider of magnetic resonance imaging (MRI) breast coils, tables and visualization software, the company will be able to demonstrate a range of MRI tools in NCBC. 

Hologic operates through four segments – Breast Health, Diagnostics, GYN (Gynecology) Surgical and Skeletal Health. The breast health being the largest segment (contributing 45% of Hologic’s total revenue with a growth of 9% year over year during the last reported quarter) provides a complete Mammography suite.

Its Selenia technology is a breast imaging platform that utilizes Tomosynthesis, to produce both three dimensional (3D) and the conventional two dimensional (2D) full field digital mammography (FFDM) images for accurate detection and treatment of breast cancer. Presently this system is installed in more than 12 countries around the world.

The growth of Breast Health segment primarily came on the back of a rise in revenues from services related to its installed base of digital mammography systems, 2D/3D Dimensions product, the inclusion of Sentinelle Medical and Eviva and Celero breast biopsy products. We expect the Breast Health segment to capture the new and unexplored market and record higher revenues going forward.

Though we are confident about the growth prospects of Hologic’s Breast Health segment based on its recent initiatives, we are concerned about the Diagnostics segment that has been suffering for the past few quarters due to economic uncertainty, resulting in lower doctor visits. Moreover, constrained capital spending is leading to lower sales, a trend that is expected to continue.

 
HOLOGIC INC (HOLX): Free Stock Analysis Report
 
Zacks Investment Research